Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | METAP2 | P50579 | 2/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
| ▸ | CTSC | P53634 | 2/20 | 0.45 |
| ▸ | METAP1 | P53582 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7613852 | 1.00 | OPRK1 (0.47) | OPRK1METAP2MMP8CTSCMETAP1 | |
| SCHEMBL7610222 | 0.91 | MME (0.51) | OPRK1CTSCMMEANPEPCTSL | |
| SCHEMBL3706481 | 0.91 | MME (0.51) | OPRK1CTSCMMEANPEPCTSL | |
| SCHEMBL29480449 | 0.85 | OPRK1 (0.57) | OPRK1MMP8CTSCTACR1HPRT1 | |
| SCHEMBL3701701 | 0.84 | PSMB5 (0.50) | MMP8CTSLCTSBTACR1 | |
| SCHEMBL7617954 | 0.84 | PSMB5 (0.50) | MMP8CTSLCTSBTACR1 | |
| Hydrochloric Acid SCHEMBL9513055 | 0.84 | OPRK1 (0.56) | OPRK1MMP8CTSCTACR1HPRT1 | |
| SCHEMBL3700091 | 0.84 | CTSL (0.53) | CTSLTACR1 | |
| SCHEMBL5020124 | 0.84 | CTSL (0.53) | CTSLTACR1 | |
| SCHEMBL30295503 | 0.83 | OPRK1 (0.55) | OPRK1MMP8CTSCTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140121202-A1 | S-t-BUTYL PROTECTED CYSTEINE DI-PEPTIDE ANALOGS AND RELATED COMPOUNDS | PROMENTIS PHARMACEUTICALS, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8624052-B2 | S-t-butyl protected cysteine di-peptide analogs and related compounds | PROMENTIS PHARMACEUTICALS, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| EP-2638005-A2 | S-T-BUTYL PROTECTED CYSTEINE DI-PEPTIDE ANALOGS AND RELATED COMPOUNDS | Promentis Pharmaceuticals, Inc. (US) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012065102-A2 | S-T-BUTYL PROTECTED CYSTEINE DI-PEPTIDE ANALOGS AND RELATED COMPOUNDS | PROMENTIS PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| US-20120122792-A1 | S-t-BUTYL PROTECTED CYSTEINE DI-PEPTIDE ANALOGS AND RELATED COMPOUNDS | PROMENTIS PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121202-A1 | S-t-BUTYL PROTECTED CYSTEINE DI-PEPTIDE ANALOGS AND RELATED COMPOUNDS | CSTB, IAPP, VIP | OPRK1 3227/4885METAP2 62/4885MMP8 2463/4885 |
| US-20120122792-A1 | S-t-BUTYL PROTECTED CYSTEINE DI-PEPTIDE ANALOGS AND RELATED COMPOUNDS | CSTB, IAPP, VIP | OPRK1 3227/4885METAP2 62/4885MMP8 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.